Carregant...
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...
Guardat en:
| Publicat a: | Antibodies (Basel) |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6698871/ https://ncbi.nlm.nih.gov/pubmed/31557983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antib5010001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|